K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.
about
Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patientsEvaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010.Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trialsChronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey.Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysisPrevalence of cardiovascular risk factors in hemodialysis patients - The CORDIAL studyOxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patientsA pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy.Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography.Predialysis therapeutic care and health-related quality of life at dialysis onset (The pharmacoepidemiologic AVENIR study).Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232].The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.Development and results of a kidney disease knowledge survey given to patients with CKD.Primary care management of chronic kidney disease.Baseline characteristics and prevalence of cardiovascular disease in newly visiting or referred chronic kidney disease patients to nephrology centers in Japan: a prospective cohort study.The association of very-low-density lipoprotein with ankle-brachial index in peritoneal dialysis patients with controlled serum low-density lipoprotein cholesterol level.Dyslipidemia associated with chronic kidney diseaseLipid levels and renal function decline in pre-dialysis patients.Dyslipidemia in children with chronic kidney diseaseSurvival Benefit of Statins in Hemodialysis Patients Awaiting Renal TransplantationAlbuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con ViewMacrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritisClinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study.Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.Reliable individualized monitoring improves cholesterol control in kidney transplant recipients.N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for Loss of Muscle Mass in Prevalent Hemodialysis Patients.What's the Optimal Lipids Level for Dialysis Patients? A Cohort Study from a Chinese Dialysis Center in a University Hospital.Efficacy of Statin Treatment in Early-Stage Chronic Kidney DiseaseHigh burden and unmet patient needs in chronic kidney disease.Therapeutic strategies to slow chronic kidney disease progression.Predictive value of conjointly examined IL-1ra, TNF-R I, TNF-R II, and RANTES in patients with primary glomerulonephritis.Predictive Factors for Coronary Artery Disease among Peritoneal Dialysis Patients without Diabetic Nephropathy.Plasma High-Sensitivity C-Reactive Protein Level is Associated with Impaired Estimated Glomerular Filtration Rate in Hypertensives.The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study.Association between LDL-C and risk of myocardial infarction in CKDTreatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results.Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant.Current advances in chronic kidney disease in children: growth, cardiovascular, and neurocognitive risk factors.The impact of chronic kidney disease on lipid management and goal attainment in patients with atherosclerosis diseases in Taiwan.
P2860
Q30432443-296A58AE-63DC-49E6-9DC4-8CE9B9B015EFQ30651756-AE59B5D9-4407-4676-BC91-585DB228F5CCQ33244366-7BEA47F9-5F22-44CF-9867-ADCEA5DF42DDQ33266310-1EC6B227-6585-4A79-B0A8-C54061D6943CQ33704372-7E69451A-ABAD-4FDA-AAD2-141887B03459Q33733420-F67068DD-A183-4D93-9848-298CFCC676CCQ33888423-C6CAEA68-9F29-4D32-978E-9B8882B233A2Q33932604-4CA0BA33-D286-4DC0-8FDC-10EFE41E7E04Q34508691-FB0EB5E8-4D95-46D6-A1A8-80EC016926BBQ34564232-A848CB7C-E935-4179-8E3D-F1D5EF5122D9Q34599557-E610042F-72D4-4441-90C2-88C28FCEB1CFQ34630074-30E2F43C-5006-436C-A046-4369D289AB7BQ34645471-2BEEB692-976D-45B1-AAA3-EB8370C1D576Q34663541-75F2AC46-34C2-4284-90D2-774E3A7020B7Q34831465-63031AF0-5777-4F9D-9DE8-E1BB07AC385CQ35007909-D10B9F25-6F49-418E-9414-7F74F89AE8FAQ35020237-E374B0AE-DEDA-4ABF-9F7C-B895D2118D5FQ35204390-6B88A03F-448F-4908-9867-E4C7F6DFBD6CQ35568634-88CD471C-AF7D-433E-B6AB-82662DBBFA56Q35675305-F2ABF882-AB00-4EF5-8680-9673563313B5Q35682234-BD8C01BE-D209-460F-8272-A414D50325FFQ35745565-C056BCEF-3E24-4896-B54C-614A4F84F2EFQ35809493-D02C3EB3-95CA-480C-9AB3-EB92215C9942Q35856929-BD446544-4F8F-4D29-B9E0-675A69785B57Q35948762-FD4BE5EE-0E99-4382-8D1D-F2E5002CF4F7Q36199888-3CC31C1E-E11C-429F-93BD-E28B13B8FAA1Q36228385-42BABD1C-6C9F-4628-99B1-2CC6F1810D59Q36247899-7EAB5928-F7D5-4F1D-ABBA-5DF64F2C7D6BQ36500612-DF4286AE-F540-40A5-9122-59B2F76737ADQ36510669-DDCC9729-D5DA-4E38-8931-21010C538CF5Q36589498-13A5B4AC-5B10-4894-AAF6-871E2F200A5AQ36594293-B70BB3A5-7924-4416-88D7-E46F2B217392Q36721445-169517D3-2463-41AC-9898-4D8BAE8C2F77Q36799725-E712BD09-0149-4D12-8AEC-FB2D9DE1A1E6Q36880435-0FAF0663-3AEE-4166-983C-AF380AD25BECQ37195404-EF551889-F6B1-4F9B-9CBA-29D0D6911575Q37353098-594AE217-9BC0-4223-983F-4F35002315E4Q37389078-77483C85-66EF-41B1-AB7B-7BF300F54D60Q37395884-40B04096-3D0E-4D17-B010-02CC3AD22566Q37605410-8AB0C7F8-074F-45A9-B9E1-A450310B2DC6
P2860
K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
K/DOQI clinical practice guide ...... patients with kidney disease.
@en
K/DOQI clinical practice guide ...... patients with kidney disease.
@nl
type
label
K/DOQI clinical practice guide ...... patients with kidney disease.
@en
K/DOQI clinical practice guide ...... patients with kidney disease.
@nl
prefLabel
K/DOQI clinical practice guide ...... patients with kidney disease.
@en
K/DOQI clinical practice guide ...... patients with kidney disease.
@nl
P1476
K/DOQI clinical practice guide ...... patients with kidney disease.
@en
P2093
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group
P304
I-IV, S1-91
P433
P577
2003-04-01T00:00:00Z